Target intelligence / Profile preview

HIF1A antisense RNA 3 (HIF1A-AS3)

Target
HIF1A-AS3
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript, Other
01

Overview

HIF1A antisense RNA 3 (HIF1A-AS3) is a long non-coding RNA (lncRNA) transcribed from the 3′ region of the HIF1A locus. It does not encode a protein but is a regulatory RNA that modulates the expression and activity of HIF1A mRNA and HIF-1α protein, a master regulator of cellular responses to hypoxia. HIF1A-AS3 positively regulates HIF1A expression in some cell types and is required for optimal HIF-1α-mediated transcription and glycolytic responses, especially under low oxygen or high glucose conditions. Functionally, it acts partly through interactions with protein partners such as PKM2 (pyruvate kinase M2) and PHD3 (prolyl hydroxylase 3), facilitating their association and nuclear translocation, which enhances HIF-1α transcriptional programs. HIF1A-AS3 expression is upregulated under hypoxia and in certain cancers, correlating with aggressive phenotypes and worse patient outcomes. Experimental knockdown of HIF1A-AS3 reduces HIF1A mRNA and protein expression, and disrupts hypoxia signaling, making it a candidate therapeutic target for nucleic acid-based approaches in cancer and other hypoxia-associated pathologies

Other names
HIFALHIF-1alpha anti-sense lncRNAHIF1A-AS3
02

Mechanism of action

For experimental drugs/therapies in research: Antisense or RNA interference-mediated knockdown reduces HIF1A-AS3, decreasing HIF1A mRNA and protein and downstream HIF-1α-mediated transcription

03

Biological functions

Regulation of HIF1A mRNA stability and expressionRegulation of HIF1A protein (HIF-1α) levelsControl of hypoxia responsesRegulation of glycolysis and glucose metabolismRegulation of gene transcription (via facilitating HIF-1α binding to DNA and activation of target genes)
04

Disease associations

Cancer (notably breast cancer)Diabetes (via regulation in hyperglycemic states)Tumor progression and angiogenesis
05

Safety considerations

High cell-type specificity of lncRNA function: blockade could affect only certain cell types, making safety/tissue selectivity a concernlncRNA stability: exceptional HIF1A-AS3 RNA stability may pose challenges for efficient knockdownRisk of affecting essential hypoxic adaptation if systemically targeted
06

Interacting drugs

None currently reported for direct targeting as an approved therapy; investigated as a potential target for nucleic acid therapeutics (NATs)
07

Biomarkers

HIF1A-AS3 expression itself (candidate biomarker for aggressive cancer, especially breast cancer)HIF1A mRNA and HIF-1α protein (as readouts of lncRNA function and intervention efficacy)

Beyond the preview

Go deeper on HIF1A antisense RNA 3 (HIF1A-AS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIF1A antisense RNA 3 (HIF1A-AS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call